106 related articles for article (PubMed ID: 21615602)
1. Epidermal growth factor receptor inhibitors in the treatment of nonmelanoma skin cancers.
Khan MH; Alam M; Yoo S
Dermatol Surg; 2011 Sep; 37(9):1199-209. PubMed ID: 21615602
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies.
Patel JD
Curr Opin Oncol; 2006 Nov; 18(6):609-14. PubMed ID: 16988582
[TBL] [Abstract][Full Text] [Related]
3. Rational bases for the development of EGFR inhibitors for cancer treatment.
Bianco R; Gelardi T; Damiano V; Ciardiello F; Tortora G
Int J Biochem Cell Biol; 2007; 39(7-8):1416-31. PubMed ID: 17596994
[TBL] [Abstract][Full Text] [Related]
4. EGFR as a target: rationale for therapy.
Wujcik D
Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):5-9. PubMed ID: 16616281
[TBL] [Abstract][Full Text] [Related]
5. Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy.
Morgillo F; Bareschino MA; Bianco R; Tortora G; Ciardiello F
Differentiation; 2007 Nov; 75(9):788-99. PubMed ID: 17608727
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor biology in head and neck cancer.
Kalyankrishna S; Grandis JR
J Clin Oncol; 2006 Jun; 24(17):2666-72. PubMed ID: 16763281
[TBL] [Abstract][Full Text] [Related]
7. Resistance to epidermal growth factor receptor-targeted therapy.
Morgillo F; Lee HY
Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of resistance to EGFR inhibitors in head and neck cancer.
Cooper JB; Cohen EE
Head Neck; 2009 Aug; 31(8):1086-94. PubMed ID: 19378324
[TBL] [Abstract][Full Text] [Related]
9. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
Tortora G; Ciardiello F; Gasparini G
Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
[TBL] [Abstract][Full Text] [Related]
10. Skin cancer chemopreventive effects of a flavonoid antioxidant silymarin are mediated via impairment of receptor tyrosine kinase signaling and perturbation in cell cycle progression.
Ahmad N; Gali H; Javed S; Agarwal R
Biochem Biophys Res Commun; 1998 Jun; 247(2):294-301. PubMed ID: 9642119
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor-targeted therapy for pancreatic cancer.
Papageorgio C; Perry MC
Cancer Invest; 2007 Oct; 25(7):647-57. PubMed ID: 18027154
[TBL] [Abstract][Full Text] [Related]
12. The role of EGFR inhibition in the treatment of non-small cell lung cancer.
Ray M; Salgia R; Vokes EE
Oncologist; 2009 Nov; 14(11):1116-30. PubMed ID: 19892771
[TBL] [Abstract][Full Text] [Related]
13. Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy.
Bianco R; Troiani T; Tortora G; Ciardiello F
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S159-71. PubMed ID: 16113092
[TBL] [Abstract][Full Text] [Related]
14. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.
Yi T; Lee HL; Cha JH; Ko SI; Kim HJ; Shin HI; Woo KM; Ryoo HM; Kim GS; Baek JH
J Cell Physiol; 2008 Nov; 217(2):409-22. PubMed ID: 18543257
[TBL] [Abstract][Full Text] [Related]
16. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
Dassonville O; Bozec A; Fischel JL; Milano G
Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
[TBL] [Abstract][Full Text] [Related]
17. Effective targeting of the epidermal growth factor receptor (EGFR) for treating oral cancer: a promising approach.
Ribeiro FA; Noguti J; Oshima CT; Ribeiro DA
Anticancer Res; 2014 Apr; 34(4):1547-52. PubMed ID: 24692681
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: differences between antibodies and TK inhibitors.
Krause M; Gurtner K; Deuse Y; Baumann M
Int J Radiat Biol; 2009 Nov; 85(11):943-54. PubMed ID: 19895271
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor inhibitors: a patent review (2010 - present).
Li SN; Li HQ
Expert Opin Ther Pat; 2014 Mar; 24(3):309-21. PubMed ID: 24387079
[TBL] [Abstract][Full Text] [Related]
20. Targeting HER1/EGFR: a molecular approach to cancer therapy.
Arteaga C
Semin Oncol; 2003 Jun; 30(3 Suppl 7):3-14. PubMed ID: 12840796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]